DDInter512 DDInter1376
Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated. The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound. This allows less frequent dosing and a lower daily dose with improvement in tolerability. Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine. Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction,
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Deutetrabenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Deutetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Deutetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Deutetrabenazine {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Deutetrabenazine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Deutetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Deutetrabenazine may lead to a major life threatening interaction when taken with Dacomitinib
Deutetrabenazine may lead to a major life threatening interaction when taken with Macimorelin